Novo Nordisk released new data that could help boost the case for the higher dose version of its blockbuster obesity injection Wegovy.

Wegovy is a medication typically prescribed for weight loss and cardiovascular risk reduction individuals with overweight or ...

A new and higher dose of obesity drug Wegovy has joined Novo Nordisk’s semaglutide portfolio, giving patients and doctors ...

Compare oral Wegovy and Foundayo weight loss pills in terms of effectiveness, side effects, and convenience to see which ...

GoodRx reports Wegovy HD is a higher-dose version of Wegovy, offering potentially greater weight loss but with increased side ...

Novo Nordisk NVO announced that the European Commission (EC) has approved a new 7.2 mg once-weekly maintenance dose of Wegovy (semaglutide injection) for adults with obesity. This provides physicians ...

A launch in the United Arab Emirates comes as Novo works to recover ground in the weight loss drug market against rival Eli ...

Novo Nordisk (CPSE:NOVO B) has launched the Wegovy pill in the UAE, the first country outside the U.S. to offer this oral obesity treatment. Regulators in the EU have issued positive opinions ...

New Wegovy trial data suggests a higher semaglutide dose may accelerate weight loss by targeting body fat more effectively while preserving muscle strength, offering promising results for long-term ...

The weight-loss drug Wegovy is now being sold in pill form, an advancement that allows users to transition away from weekly injections. It's the first GLP-1 weight-loss medication to become available ...